- Conditions
- Postmenopausal Osteoporosis
- Interventions
- abaloparatide, abaloparatide solid microstructured transdermal system
- Combination Product
- Lead sponsor
- Radius Health, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years · Female only
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Glendale, Arizona + 65 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 70
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Albiglutide Liquid Auto-injector, Albiglutide Lyophilized DCC Pen Injector, Placebo Liquid Auto-injector, Placebo Lyophilized DCC Pen injector
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Primary Hypercholesterolemia, Mixed Dyslipidemia
- Interventions
- Evolocumab AMD, Evolocumab AI/pen
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Encino, California • Thousand Oaks, California + 18 more
- Conditions
- Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
- Interventions
- Evolocumab, Routine Lipid Management
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 6,019 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Lyophilized albiglutide DCC pen injector, Lyophilized albiglutide DCC pen injector matching placebo, Albiglutide liquid auto-injector, Albiglutide liquid auto-injector matching placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 62 more
- Conditions
- Cocaine Use Disorder
- Interventions
- Exenatide, Placebo
- Drug
- Lead sponsor
- Christopher D. Verrico
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin, Semaglutide, Dapagliflozin, Placebo to Dapagliflozin
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Williamsville, New York
- Conditions
- Primary Brain Tumors, Metastatic Malignant Neoplasm to Brain
- Interventions
- 4-Demethyl-4-cholestryloxycarbonylpenclomedine
- Drug
- Lead sponsor
- DEKK-TEC, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 3
- States / cities
- New Orleans, Louisiana • Lansing, Michigan • Houston, Texas
- Conditions
- Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
- Interventions
- Palopegteriparatide Experimental Arm, Palopegteriparatide Control Arm
- Combination Product
- Lead sponsor
- Ascendis Pharma Bone Diseases A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 9
- States / cities
- Greeley, Colorado • Chicago, Illinois • Minneota, Minnesota + 5 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Albiglutide 50 mg, Placebo, CCK (Kinevac)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
- Interventions
- TransCon PTH, Placebo
- Combination Product
- Lead sponsor
- Ascendis Pharma Bone Diseases A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 9
- States / cities
- San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 6 more
- Conditions
- Migraine
- Interventions
- Erenumab, Placebo, Erenumab PFS, Erenumab AI/Pen
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 483 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Long Beach, California • National City, California + 36 more
- Conditions
- Healthy Subjects
- Interventions
- PF-06410293 PFS, PF-06410293 PFP
- Device
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Fracture of Pelvis (Disorder)
- Interventions
- Abaloparatide 80 micrograms per Pen dose, Placebo prefilled injector pen
- Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- New York, New York • Valhalla, New York
- Conditions
- Nausea
- Interventions
- Bremelanotide, Zofran, Placebo
- Drug
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 228 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Growth Hormone Deficiency (GHD)
- Interventions
- MOD-4023
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 3 Years to 11 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Type 2 Diabetes
- Interventions
- LY3437943, Dulaglutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 40
- States / cities
- Sheffield, Alabama • Canoga Park, California • Fresno, California + 36 more
- Conditions
- Overweight, Obese, Type 1 Diabetes Mellitus
- Interventions
- CT-868, CT-868 Pen Injector, CT-868 Pen Injector, Placebo
- Drug · Device
- Lead sponsor
- Carmot Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 22
- States / cities
- Concord, California • Escondido, California • Aurora, Colorado + 17 more
- Conditions
- Hyperlipidemia
- Interventions
- Atorvastatin, Placebo to Atorvastatin, Placebo to Ezetimibe, Ezetimibe, Placebo to Evolocumab, Evolocumab
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 18
- States / cities
- Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 15 more
- Conditions
- Diabetes Mellitus, Type 2, Patient Discharge, Blood Glucose, Low, Blood Glucose, High
- Interventions
- Discharge Order Set (DOS), Enhanced Standard Care (ESC)
- Other
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
- Interventions
- Alirocumab, Placebo
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Achondroplasia
- Interventions
- BMN 111 administration via Injector Pen, BMN 111 administration via vial and syringe
- Combination Product · Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Obesity
- Interventions
- CagriSema (cagrilintide B and semaglutide I), CagriSema A
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Hypersensitivity, Immediate, Hypersensitivity, Delayed, Hypersensitivity Response
- Interventions
- Direct oral penicillin challenge, Standard of care
- Other
- Lead sponsor
- Austin Health
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Nashville, Tennessee